ABIOのチャート
ABIOの企業情報
| symbol | ABIO |
|---|---|
| 会社名 | ARCA biopharma Inc. （ARCAバイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 エーアルシーエー・バイオファマ（ARCA biopharma Inc.）は主に心不全及びその他心臓血管疾患のための遺伝子をターゲットにした治療法の開発に従事するバイオ医薬品企業。同社の主要候補製品の「Gencaro TM（ブシンドロール塩酸塩）」は、慢性心不全（HF）治療のために開発されている薬理学的特性を持つβ［ベータ］遮断薬及び血管拡張剤である。同社はLabCorp社と提携して、「Gencaro」に対する臨床反応を予測できる遺伝子マーカーのためのコンパニオン・テストであるGencaroテストを行っていた。同社の候補製品は「Gencaro（ブシンドロール塩酸塩）」は、慢性心不全（HF）治療のために開発されている薬理学的特性を持つβ［ベータ］遮断薬及び血管拡張剤である。「Gencaro」は心臓神経系においてβ-1とβ-2両方の受容体を遮断する性質を持っているため、β遮断薬クラスの化合物の一部として見なされる。これらの受容体の遮断を通して、「Gencaro」はこれらの受容体を活性化する用のその他分子との結合を防ぐ。 ARCAバイオファ―マは、米国のバイオ医薬品企業。心血管疾患の遺伝的標的治療の開発を中心に事業を展開。主要製品候補として、心不全および左心室機能障害の患者向けに心房細動治療のためのβ遮断薬、および軽度の血管拡張剤であるGencaro（ブシンドロ―ル塩酸塩）の開発を手掛ける。 ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease. |
| 本社所在地 | 11080 CirclePoint Road Suite 140 Westminster CO 80020 USA |
| 代表者氏名 | Robert E. Conway ロバート・E・コンウェイ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 720-940-2200 |
| 設立年月日 | 33817 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 14人 |
| url | http://arcabio.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/abio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.67700 |
| 終値（lastsale） | 0.6301 |
| 時価総額（marketcap） | 8773402.1325 |
| 時価総額 | 時価総額（百万ドル） 8.61467 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.02033 |
| 当期純利益 | 当期純利益（百万ドル） -13.48100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Arca Biopharma Inc revenues was not reported. Net loss decreased 51% to $4.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.07 to -$0.35. |
ABIOのテクニカル分析
ABIOのニュース
ARCA biopharma''s Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study 2022/04/01 11:09:26 Benzinga
ARCA biopharma Inc (NASDAQ: ABIO ) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit; however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 … Full story available on Benzinga.com
ABIO stock falls as COVID-19 trial fails to meet key goal (NASDAQ:ABIO) 2022/03/31 20:42:14 Seeking Alpha
Arca Biopharma (ABIO) is trading ~28% lower in the post-market Thursday after the clinical-stage biotech announced that its experimental COVID-19 therapy rNAPc2 failed to meet the…
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial 2022/03/31 20:15:00 GlobeNewswire
WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19 , a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 compared to standard of care heparin.
ARCA biopharma GAAP EPS of -$1.39 (NASDAQ:ABIO) 2022/03/14 21:40:36 Seeking Alpha
ARCA biopharma press release (ABIO): FY GAAP EPS of -$1.39.FY Cash and cash equivalents of $53.4M
ARCA biopharma Inc Shares Approach 52-Week Low - Market Mover 2022/01/09 19:19:27 Kwhen Finance
ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. The stock is currently down 5.1% year-to-date, down 51.7% over the past 12 months, and down 96.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 1.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -1436.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
ARCA biopharma Inc Shares Close in on 52-Week Low - Market Mover 2021/12/30 07:02:38 Kwhen Finance
ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. The stock is currently down 44.4% year-to-date, down 46.4% over the past 12 months, and down 95.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 17.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -268.9% The company's stock price performance over the past 12 months lags the peer average by -299.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Financial Survey: ARCA biopharma (ABIO) & Its Peers 2021/12/13 11:20:42 Transcript Daily
ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations. Risk & Volatility ARCA biopharma has []
Head-To-Head Contrast: ARCA biopharma (ABIO) and Its Peers 2021/12/11 09:12:42 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Risk and Volatility ARCA biopharma has []
Contrasting ARCA biopharma (ABIO) & Its Peers 2021/12/10 10:58:42 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its peers? We will compare ARCA biopharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current []
ARCA biopharma (ABIO) vs. Its Peers Critical Analysis 2021/12/09 11:36:46 Transcript Daily
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk. Valuation & Earnings This table compares []
Head-To-Head Comparison: ARCA biopharma (ABIO) versus The Competition 2021/12/03 04:10:42 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk ARCA biopharma has []
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 2021/12/02 13:30:00 Intrado Digital Media
WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN - COVID - 19 , the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. 160 patients were enrolled at clinical investigative sites in the United States, Argentina and Brazil. The Company anticipates reporting topline data from the clinical trial in the first quarter of 2022.
Head to Head Survey: ARCA biopharma (ABIO) vs. Its Rivals 2021/11/27 07:48:41 Transcript Daily
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its peers? We will compare ARCA biopharma to related companies based on the strength of its valuation, profitability, earnings, institutional ownership, risk, analyst recommendations and dividends. Profitability This table compares ARCA biopharma and its []
Reviewing ARCA biopharma (ABIO) & Its Rivals 2021/11/26 04:17:01 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related companies based on the strength of its risk, profitability, earnings, institutional ownership, dividends, analyst recommendations and valuation. Analyst Recommendations This is a breakdown []